论文部分内容阅读
目的观察莫沙必利联合乳果糖预防和治疗肿瘤患者化疗后便秘的临床疗效。方法将94例患者随机分为观察组47例和对照组47例,二组均于化疗前3d开始,每日早餐时口服1次乳果糖口服液30ml,服用至化疗结束。观察组加用枸橼酸莫沙必利分散片5mg饭前口服,3次/d。观察患者化疗后便秘发生率及出现便秘后缓解时间的变化情况。结果观察组在便秘的发生率及发生便秘后缓解时间二方面,临床疗效均明显优于对照组(P<0.05)。结论莫沙必利联合乳果糖预防和治疗肿瘤患者化疗后便秘有较好的临床疗效,值得临床推广应用。
Objective To observe the clinical efficacy of mosapride combined with lactulose in preventing and treating constipation after chemotherapy in cancer patients. Methods Ninety-four patients were randomly divided into observation group (n = 47) and control group (n = 47). The two groups were started three days before chemotherapy. 30ml of lactulose oral solution was orally taken once daily for breakfast until the end of chemotherapy. Observation group plus mosapride citrate dispersible tablets 5mg orally before meals, 3 times / d. The incidence of constipation after chemotherapy and the change of relief time after constipation were observed. Results The observation group was significantly better than the control group in the incidence of constipation and the time of relief after constipation (P <0.05). Conclusion Mosapride combined with lactulose in the prevention and treatment of cancer patients with constipation after chemotherapy has better clinical efficacy, it is worthy of clinical application.